Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

The drugmaker released data early on Tuesday for one of Metsera’s drugs showing people on the medication lost up to 12.3% of ...

Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera Inc. The ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.